Recent polls paint a mixed picture of physicians' willingness to see pharma sales reps. What gives? Are no-see docs up or down, and what's behind the dissonant findings?
Curating personal relationships is one of the most valuable functions medical marketers can provide. The best way is through face-to-face interaction.
Sales of cystic-fibrosis drug Orkambi higher than expected; new sensor tracks sweat; J&J develops clinical trial to find new way to treat depression
Valeant says it lost few reps despite business scrutiny; Novartis CEO says drugmakers must share benefits of new medicines with other healthcare stakeholders; Bloomberg analysis finds US pays more for branded drugs after discounts
The contract sales organization plans to sell its commercial services business to Publicis Healthcare Communications Group.
A pair of surveys paint a complicated picture of what direction pharma access to healthcare providers is going.
Accenture found that life-sciences executives believe that smart tools and devices will be the catalyst for drugmakers to move forward with beyond-the-pill initiatives.
Sprout plans to hire 200 sales reps, targeting 30,000 doctors, to accompany the drug's launch.
Copaxone sales rise despite generic competition; Valeant to defend tax strategy; Bristol-Myers Squibb to test Opdivo with mogamulizumab in the US
View on a quarter-by-quarter basis the competitive market for four new hepatitis-C treatments and track how Gilead Sciences' Harvoni became the market leader within months of receiving approval from the FDA.
- Five things for pharma marketers to know: Friday, February 5, 2016
- Why Gathering Health Economic Data for Cancer Drugs is Now Essential
- Ascension Health ups Ragone to chief marcomms officer
- House Oversight committee upbraids Turing, Valeant execs
- Burcin departs Havas network for Klick Health in senior-staffing push